Sanofi chief highlights high hopes for liver cancer drug

Sanofi has high hopes for a pre-clinical therapy it believes can fight liver cancer in China. In an interview with Reuters in Hong Kong, Sanofi CEO Chris Viehbacher (photo) said that investigators would push ahead with the first human studies of the therapy, called slit-trap, next year. Sanofi ($SNY) is one of a number of biopharma outfits that has big expectations for the Chinese drug market in years to come, with a large budget for burgeoning research operations in Asia. Liver cancer, which is rife in China and rare in the West, makes a good initial target for them to go after. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.